S 1462 New York Senate · 2021 Regular Session

Relates to dihydropyrimidine dehydrogenase deficiency testing

Summary
Requires dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrmidine or other antimetabolite treatment; requires policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; provides for dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program.
Bill status in committee 1 of 4 stages cleared
Introduction
Jan 2021
Committee Review
Floor Vote
Governor
Introduced Jan 12, 2021 Last action Jan 5, 2022
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
2
Key actions
0
Committee
2
Jan 5, 2022
Committee
REFERRED TO HEALTH
upper
Jan 12, 2021
Committee
REFERRED TO HEALTH
upper
1 primary · 0 co-sponsors

Sponsors

Role
Legislator
Party
State
District
P
NB
Neil Breslin
DDemocratic/Working Families
NY
46